INO-5150 in early treatment of biochemically recurrent prostate cancer

In 2015, Inovio Pharmaceuticals started a Phase I trial of INO-5150 — a new type of immunotherapy using a DNA vaccine for prostate cancer which targets both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA). … READ MORE …

INO-5150 enters initial clinical trials

Inovio Pharmaceuticals is initiating a Phase I trial of INO-5150 — a new type of immunotherapy for prostate cancer which targets both the prostate-specific antigen (PSA) and the and the prostate specific membrane antigen (PSMA). … READ MORE …